We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Trifluridine and Tipiracil for Metastatic Gastric Cancer – third line and above

< Back

Trifluridine and Tipiracil for Metastatic Gastric Cancer – third line and above


Cancer and Palliative Care

July 2018

Gastric cancer is cancer that starts anywhere inside the stomach or the stomach wall. Advanced gastric cancer can be locally advanced (has spread into the tissues around the stomach) or metastatic (has spread to at least one other part of the body such as the liver). Most gastric cancer cases are diagnosed at a late stage and in people aged 75 years and over. Advanced cancers have poor prognosis and usually cannot be cured. However, they may be controlled, and symptoms can be relieved through treatment.
Trifluridine in combination with tipiracil in a single oral tablet, is in development for the treatment of metastatic gastric cancer, in patients who are refractory (resistant) to two prior standard treatments for the advanced disease. Trifluridine is incorporated into the DNA where it prevents cells from dividing and multiplying. The addition of tipiracil helps increase the level of trifluridine in the blood by slowing its breakdown. If licensed, trifluridine in combination with tipiracil will be an additional treatment option for patients with gastric cancer who have failed two prior therapies, who currently have very few treatment options available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts